Keywords: novo, nordisk, gains, recombinant, factor, xiii, usa-based

Novo Nordisk gains recombinant Factor XIII

Article | 11 October 2004

USA-based ZymoGenetics has licensed to Denmark's Novo Nordisk exclusive worldwide rights to its recombinant Factor XIII portfolio, including all related ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novo Nordisk

Go to company listing

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Go to drug listing